Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Astellas' biologics cornerstone

In March, Astellas Pharma Inc. took its first steps toward joining an increasingly long line of pharmaceutical companies that are bringing biologics capabilities in-house via two deals that gave it access to antibody generation technologies. Last week, Astellas brought in the remaining pieces of its biologics value chain by acquiring Agensys Inc. for $387 million in

Read the full 567 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE